Title : Anticancer response to disulfiram may be enhanced by co-treatment with MEK inhibitor or oxaliplatin: modulation by tetrathiomolybdate, KRAS/BRAF mutations and c-MYC/p53 status.

Pub. Date : 2019

PMID : 30792807






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Anticancer response to disulfiram may be enhanced by co-treatment with MEK inhibitor or oxaliplatin: modulation by tetrathiomolybdate, KRAS/BRAF mutations and c-MYC/p53 status. Oxaliplatin KRAS proto-oncogene, GTPase Homo sapiens